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Activeanticancermoleculeshavebeensearched fromnaturalproducts; manydrugs weredevelopedfromeithernaturalproductsor
their derivatives following the conventional pharmaceutical paradigm of drug discovery. However, the advances in the knowledge
ofcancerbiologyhaveledto personalizedmedicine usingmolecular-targeted agentswhich create new paradigm.Clinicalbeneﬁt is
dependent onindividual biomarkerandoverall survival is prolonged through cytostatic rather thancytotoxic eﬀects to cancer cell.
Therefore, adiﬀerent approach isneeded fromthesingleleadcompoundscreening model basedoncytotoxicity. In ourexperience,
the Rhus verniciﬂua stoke (RVS) extract traditionally used for cancer treatment is beneﬁcial to some advanced cancer patients
though it is herbal extract not single compound, and low cytotoxic in vitro. The standardized RVS extract’s action mechanisms
as well as clinical outcomes are reviewed here. We hope that these preliminary results would stimulate diﬀerent investigation in
natural products from conventional chemicals.
1.Introduction
OnSeptember6, 2008,thearticleofthetitle“We foughtcan-
cer... and cancer won” was in the Newsweek. The subtitle
was that it is time to rethink the war on cancer, after billions
spent on research and decades of hit or miss treatments.
The improved understanding of molecular biology in cancer
research has led to a number of new, eﬀective treatments
forcancer. However, the age-standardized deathrate from all
types of cancers combined ﬁrst increased from 1970 to 1990
and then decreased through 2002, yielding a net decline of
2.7% [1]. Therefore, it is necessary to understand the cancer
from a diﬀerent point of view, which has been helped by the
oriental medicine.
In view of the oriental medicine, mass or nodule is re-
sulted from Qi and Blood stagnation. The development of
a tumor could be interpreted as Qi Stagnation induced by
stress, emotional disturbances, or external factors which
could progress into Blood stagnation or stasis [2]. Tradition-
ally Rhus verniciﬂua stoke (RVS) was considered to have the
function of breaking up blood stasis and purging hardness
[3]. Therefore, it could be applied for cancer treatment. RVS
oftheAnacardiaceaefamily, commonlyknown asthelacquer
tree,wasdocumentedtobeusedfortreatingvariousstomach
diseases, including tumor in East Asia including Korea at
the 15th century [4, 5]. Recently several experimental stud-
ies showed that ﬂavonoids from RVS have eﬀective anti-
proliferative and apoptotic activities on various tumor cell
lines including human lymphoma, breast cancer, osteosar-
coma, and transformed hepatoma cells [4–7].
However, theclinical applicationofRVS has been limited
because an allergenic component, urushiol, causes severe
contact dermatitis in sensitive individuals [8, 9]. Therefore
urushiol, a mixture of several derivatives of catechol, should
be removed from RVS for pharmaceutical use. A standard-
ized extract of allergen-removed RVS was manufactured2 Journal of Biomedicine and Biotechnology
based on traditional method. Our integrative cancer center
composed of oncologists and oriental medicine doctors was
founded in June, 2006, and the standardized RVS extract
was prescribed for the purpose of prolonging survival and
improving the quality of life in patients with only palliative
therapy available. Here, we review on the action mechanism
and best outcomes of the standardized RVS extract with or
withoutconventionaltreatment inpatientswith advanced or
metastatic cancer.
2.Preparationsof Standardized
ExtractfromRVS
RVS stalk, which was 10 years old and grown in Wonju,
Republicof Korea, was dried without exposure to direct sun-
light and chopped up. The pieces were roasted in an iron pot
at 240◦C for 50 minutes to remove allergens and extracted
two times with a 10-fold volume ofwater at 90◦Ct o9 5 ◦Cf o r
6hours(Koreanpatentno.0504160).Theextract wasﬁltered
with Whatman GF/B ﬁlter paper and concentrated under
vacuum to remove water. The concentrate was lyophilized
to a brownish powder. The extraction yield from 100g of
chopped material was 3.3g. A component analysis method
using high-performance liquidchromatography showed that
the RVS extract contained fustin, ﬁsetin, sulfuretin, and
butein, among others. The quality of the RVS extract was
tested and controlled according to the quality standards of
the Korea Food & Drug Administration and our hospital’s
standards (fustin > 13.0%, ﬁsetin > 2.0%, urushiol not
detected). Daily oral administration is 1350mg (1 capsule
containing 450mg three times a day) of RVS extract.
3.Mechanism Studies
3.1. Anti-Angiogenesis. The RVS was experimentally shown
to have antitumor properties in carcinoma of breast and
uterine cervix in vitro and suppress tumor volume in a
xenograft mouse model system using A549 nonsmall cell
lung cancer and Lewis lung cancer cells in vivo through
inhibitingtheproliferationandmigratoryactivityofvascular
endothelial growth factor [10, 11]. It also signiﬁcantly inhib-
ited proliferation of human umbilical vein endothelial cells
(HUVECs) induced by vascular epithelial growth factor
(VEGF), despite its weak cytotoxicity against HUVECs.
Migration of endothelial cells toward a chemoattractant
is an important step in angiogenesis [12]. When VEGF alone
was present, the wound after scratching the cell monolayer
was closed by cell migration. However, the addition of RVS
signiﬁcantly inhibited VEGF-induced migration of HUVECs
similar to control cells (Figure 1). Maturation of migrated
endothelial cells into a tube-like structure is a critical step
for formation of functional vessels. HUVECs were seeded
onto Matrigel and stimulated to form capillary networks
with VEGF. As shown in Figure 2(b), robust and complete
tube network formation was observed in VEGF-stimulated
H U V E C s .H o w e v e r ,t h i se ﬀect of VEGF was signiﬁcantly
inhibited by RVS showing incomplete sprouting or branch-
i n gorbr ok enn etw or kbetw eentubesofHUV ECs(Fi gur e2).
These results indicate that RVS blocks migration and matu-
ration of endothelial cells induced by VEGF.
3.2. Anti-Invasion. Matrix metalloproteinases (MMPs) are
a family of zinc-dependent endopeptidases that remodel
and degrade the extracellular matrix (ECM). Cancer cell
migration and invasion of surrounding tissues are mediated
in part by MMPs, especially MMP-2 and MMP-9 [13]. The
eﬀect of RVS on the invasiveness of human ﬁbrosarcoma
HT1080cellswasinvestigatedbyBoydenchamberassay [14].
The invasiveness of HT1080 cells was reduced in a dose-
dependent manner following 24-hour treatment of up to
RVS 200μg/mL (Figure 3). The ability of RVS extract to
inhibit the secretion of MMP-2 and MMP-9 from HT1080
cells was studied. The levels of MMP-2 and MMP-9 were
reduced by RVS, suggesting that the decrease in HT1080
cell invasion is a consequence, at least in part, of reduced
activities of both MMP-2 and MMP-9. RVS inhibited MMP-
2 and MMP-9 activities with IC50 value of 1.01 ± 0.07μg/mL
and 1.94 ± 0.11μg/mL, respectively, by spectroﬂuorometric
method which is very low concentration compared to other
various herbs [15]( F i g u r e4).
4.ClinicalStudies
4.1. Non-Small Cell Lung Cancer (NSCLC) [16]. The RVS
was investigated to prolong survival in NSCLC after the fail-
ure of ﬁrst-line or second-line chemotherapy. Forty patients
treated with RVS for previously treated, advanced NSCLC
between June 2006 and June 2009 were eligible for the ﬁnal
analysis.ThemedianRVSadministration periodwas75days.
The median survival time was 8.4 months with a 1-year
survival of 40%, and the disease control rate was 63.6%,
which is compatible with external controls in second-line
chemotherapy. RVS showed more favorable outcomes in
patients with better performance status or adenocarcinoma
in terms of overall survival. The common RVS-related ad-
verse events were mild epigastric pain and pruritis.
4.2. Colorectal Cancer (CRC) [17]. From July 2006 to No-
vember 2007, patients with conventional chemotherapy re-
fractory metastatic CRC were checked. After fulﬁlling inclu-
sion/exclusion criteria, 36 patients were eligible for the ﬁnal
analysis. Overall survival and adverse events of patients
treated with RVS in the aftercare period were determined.
The median RVS administration period was 2.7 months.
The median overall survival for the entire population was
10.9 months (95% conﬁdence interval, 5.6–16.1) and 1-year
survival rate was 44.4%, which is compatible with external
controls. Bysurvival analysis using Coxproportionalhazards
model, the performance status and the prior chemotherapy
regimen number signiﬁcantly aﬀected overall survival.
4.3. Pancreatic Cancer. Palliative chemotherapy-na¨ ıve pa-
tients with advanced or metastatic pancreatic adenocarci-
noma were checkedfromJuly 2006toJune 2010.Afterapply-
ing inclusion/exclusion criteria, 42 patients were eligible
for the ﬁnal analysis. Overall survival, clinical beneﬁt, andJournal of Biomedicine and Biotechnology 3
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Figure 1: Eﬀects of the standardized RVS extract on the migratory activity of VEGF-stimulated HUVEC (Wound-healing test). (a) The
migrated cells in window-scraped ﬁeld after scratching the cell monolayer; Control. (b) The wounds closed by cell migration from the
wound edge after VEGF alone. (c) VEGF plus RVS (50μg/mL). (d) VEGF plus RVS (100μg/mL) showing inhibitory eﬀect on migration
compared to only VEGF-treated control.
(a) (b)
(c) (d)
Figure 2: Eﬀects of the standardized RVS extract on the tube formation in VEGF-stimulated HUVECs. (a) HUVECs seeding in Matrigel
form capillary networks; Control. (b) The robust and complete tube network formation after VEGF alone. (c) VEGF plus RVS (50μg/mL).
(d) VEGF plus RVS (100μg/mL) showing inhibitory eﬀect on tube network formation compared to only VEGF-treated control.4 Journal of Biomedicine and Biotechnology
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Figure 3: The eﬀect of the standardized RVS extract on the invasiveness of human ﬁbrosarcoma HT1080 cells using Boyden chamber assay.
(a) Control. (b) RVS 50μg/mL. (c) RVS 100μg/mL. (d) RVS 200μg/mL showing inhibitory eﬀect on invasion compared to the control.
adverse eventsofthese patients treated with RVS in the after-
care period were determined. The mean RVS administration
period was 3.86 months (95% conﬁdence interval: 2.52–
5.20). The median overall survival for the entire population
was 7.87 months, and 1-year survival rate was 26.2%, which
is compatible with external controls. By using univariate
and multivariate analyses, RVS treatment including the per-
formance status and prognostic index signiﬁcantly aﬀected
overall survival. A clinical beneﬁt response was also shown
by RVS treatment which was not dependent on concurrent
chemotherapy (Data not published).
5.CaseStudies
5.1. Hepatic Cellular Carcinoma (HCC) [18]. A 62-year-old
man underwent living donor liver transplantation for both
hepatocellular carcinoma and end stage liver disease in
March 2005. He had been diagnosed with hepatitis C infec-
tionin 1977. Unfortunately, the HCC recurred with multiple
metastases in both lungs in September 2005, 6 months after
livertransplantation. Aftersystemic doxorubicinchemother-
apy showed progression of lung metastases, he began receiv-
ingonlyRVStreatmentinJune2006.CTscans5monthslater
showed marked shrinkage of the lung metastases. Moreover,
the patient tolerated the RVS well, without hematologic
and nonhematologic toxicity. Four months later, metastatic
mass in the right lower lobe of lung had increased in
April 2007. The patient discontinued the RVS treatment
and underwent radiation therapy. After ﬁnishing radiation
therapy, he developed new liver metastases and died of
progressive disease in November 2007.
5.2. Gastric Carcinoma [19]. An 82-year-old female was dia-
gnosed with gastric cancer with a polypoid gastric mass ap-
proximately 25mm in diameter at the middle body portion
of the lesser curvature, a ﬂat elevated lesion 50mm in diam-
eter at the prepyloric antrum, and the small gastrohepatic
lymph nodes in October 2006. The endoscopic biopsy
conﬁrmed well-diﬀerentiated adenocarcinoma with a muta-
tion in p53 that showed high nuclear activity of more
than 80%. Gastrectomy was not done because of old age
and the concerns about the quality of life after surgery.
RVS treatment was exclusively initiated on September 25,
2006. Five months later, the polypoid mass had markedly
decreased and the ﬂat elevated lesion had shrunk slightly,
although the gastrohepatic lymph nodes were not changed.
The biochemical parameters associated with liver and renal
function were within the normal range, and no signiﬁcant
adverse eﬀects from her RVS treatment have been observed.
She maintains a good performance status up to now (July
2011).
5.3. Renal Cell Carcinoma (RCC) [20]. A 47-year-old man
presented a 12cm right renal mass and received a right radi-
cal nephrectomy which was pathologically the clear cell type
of RCC in July 2006. Four months later, follow-up CT and
PET scans revealed metastatic multiple pulmonary nodules.
Palliativechemotherapywasrecommended,butherefusedit.Journal of Biomedicine and Biotechnology 5
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Figure 4:Theeﬀect ofthestandardized RVS extract onmatrixmet-
alloproteinase (MMP) activities by spectroﬂuorometric method.
The IC50 of the standardized RVS extract for MMP-2 and MMP-
9 was 1.01 ± 0.07μg/mL and 1.94 ± 0.11μg/mL respectively. ∗P<
0.05 versus respective controls.
Instead, only RVStreatment was initiated inDecember2006.
After 4 months, CT scans showed a complete response in
all pulmonary metastases including resolution of right pul-
monary artery thrombosis. Follow-up CT scans continued
to demonstrate a complete response. He maintains a good
performance status up to now (July 2011).
A 47-year-old man was diagnosed with the clear cell
type of RCC accompanying multiple pulmonary nodules
and underwent a radical nephrectomy for a 6.3cm mass in
September 2006. After cytoreductive surgery, the metastases
in both lungs aggravated and a right adrenal mass was
newly developed. After palliative sunitinib 2 cycles showed
progression of lung metastases and both adrenal masses, he
began receiving only RVS treatment in July 2007. After 9
months of RVS administration, chest CT scans showed the
resolution of the masses, noted previously in the left upper
lung. After 13 months of RVS therapy, CT scans showed
signiﬁcant reduction in the size of the metastatic masses in
both adrenal glands. No evidence of disease continues in CT
scans obtained up to now (July 2011).
5.4. NSCLC [21]. A 52-year-old female was diagnosed with
pulmonary adenocarcinoma accompanying malignant pleu-
ral eﬀusion conﬁrmed by histologic examination in August
2006. Immunochemical staining pattern was a cytokeratin
7 (strong positive), cytokeratin 20 (negative), and thyroid
transcription factor-1 (positive). One month later, CT scans
showed an aggravation in malignant pleural eﬀusion. She
strongly refused recommended chemotherapy because of
concerns about adverse eﬀects. Instead, only RVS treatment
wasinitiated inOctober2006.After1-month RVStreatment,
CT scans showed marked decrease in pleural eﬀusion and
no interval change in mass. There was no signiﬁcant change
in tumor and pleural nodularity in a chest CT scans until
January 2009. After progression of her disease, she was
enrolled in a clinical trial (erlotinib) at other hospital in July
2009 and was lost to follow-up. Adverse eﬀects from 34-
month RVS treatment were not observed.
6.Discussionand Conclusion
As several plants were used for cancer in traditional practice,
rigorous in vitro and in vivo studies are essential and
necessary to evaluate these extract’s eﬃcacy and safety
before clinical trials, where the eﬃcacy is dependent on the
cancer-cell toxicity. Throughout this drug screening model
such as the US National Cancer Institute (NCI) 60 human
tumor cell line anti-cancer drug screen (NCI60) based on
cytotoxicity, many drug developments could be possible
from natural products [22]. In fact, half of all anti-cancer
drugs approved internationally were either natural products
or their derivatives and were developed on the basis of
knowledge gained from small molecules or macromolecules
that exist in nature [23]. However, it is questionable that the
cell death is a critical end point for anti-cancer treatments.
T h e s ed a y s ,t h ea d v a n c e si nt h ek n o w l e d g eo fc a n c e rb i o l o g y
have developed some molecular-targeted agents for cancer
treatment. Multiple tyrosine kinase inhibitors targeted on
angiogenesis clinically prolong overall survival through
cytostatic rather than cytotoxic eﬀect to the cancer cells
[24].
Korean health care system is diﬀerent from other coun-
tries where two separate medical systems, western medicine
and traditional Korean medicine, exist. The natural extract
administered traditionally could be legally prescribed by
traditional Korean medicine doctors. Therefore, it is possible
for cancer patients to receive medication which might not be
approved on conventional drug screen model because of low
cytotoxicity. In fact, the RVS extract gave poor outcomes in
NCI60 cell lines (Data not shown). However, some cancer
patients in our center survived advanced cancer and are
practically proven as responder to RVS extract. Except all
previouslydescribedpatientstobepublished,thereare many
responders in various cancer cell types including pancreatic
cancer, cholangiocarcinoma, and sarcoma refractory to con-
ventional chemotherapy. We suggest that standardized RVS
extract could be a natural anticancer candidate from our
experiences.
Single active constituents such as sulfuretin or butein
have been characterized from RVS extract, following the
conventional pharmaceutical paradigm of drug discovery
[25, 26]. Nevertheless, it is hypothesized that the active
compound isolated from plants may rarely have high activity
against cancer as the extract at comparable concentra-
tion without synergistic interaction or multifactorial eﬀects
between compounds present in herbal extracts [27]. Cancer
is also complex disease having various biological capabilities
such as sustaining proliferative signaling, evading growth6 Journal of Biomedicine and Biotechnology
suppressors, resisting cell death, enabling replicative immor-
tality, inducing angiogenesis, activating invasion and metas-
tasis, genome instability, tumor-promoting inﬂammation,
deregulating energy metabolism, and evading immune de-
struction [28]. In response to targeted therapy, cancer cells
may also reduce their dependence on a particular capability,
becoming resistant to it. For example, even if potent angio-
genesis inhibitors succeed in suppressing speciﬁc molec-
ular targets, tumors adapt and shift from a dependence
upon continuing angiogenesis to invasiveness and metastasis
instead [28, 29]. Therefore, multiple targeted agents with
synergistic interaction are necessary to inhibit the cancer cell
progression.Thewholeextractcontainingmanyconstituents
f r o mn a t u r a lp r o d u c t sm i g h tm a k ei tp o s s i b l et ob em o r e
eﬀectiveandlesstoxicinclinicthansinglepotentcompound.
Based on clinical outcomes of RVS, it could be postulated
to have various therapeutic targeting on cancer cell except
the previously mentioned mechanism of action focused on
angiogenesis.
In the era of targeted therapy, the predictive biomarkers
have been identiﬁed to select patients more likely to beneﬁt
from it, which indeed makes cancer treatment personal-
ized. In recent development of new drug, well-validated
biomarker becomes more and more important from the
excellent example of crizotinib targeting ALK mutation
[30]. Unfortunately, there are no known clinically relevant
biomarkers which could identify responders to the drugs
targeted on angiogenesis [31]. Therefore, more research
is needed for the predictive factors in order to ﬁnd RVS
extract-responders using molecular biology and traditional
Korean medicine’s diagnostic methodology. From our clin-
ical results, eﬀective outcome from RVS extract is not
dependent on not only the cancer type but also the patient.
Natural products are also known to aﬀect immune function
which could be monitored by immunomodulating cytokines
such as IFN-γ, IL-2, and IL-10 [32]. Actually, there are
reports on anti-inﬂammatory function of RVS or RVS
ﬂavonoids.ButeinfromRVSinhibitscytokine-inducednitric
oxide production by suppression of inﬂammatory signaling
in NF-κBp a t h w a y s[ 33]. RVS hexane fraction and its
major component, ﬁsetin, signiﬁcantly inhibit inﬂamma-
tory cytokine production such as TNF-α,I L - 6 ,I L - 8 ,a n d
monocyte chemoattractant protein-1 [34]. RVS glycoprotein
(36kDa) also has an inhibitory activity of T-helper type 2
(Th2) cytokines such as IL-4 and IL-10, which means to help
immune dysfunction [35]. In aggressive pancreatic cancer, a
cross talk between tumor cells and cancer-associated ﬁbrob-
lasts was reported to result in the induction of Th2-type
inﬂammation which was well correlated with poor survival
of patients [36]. Therefore, we try to focus cytokines-related
immune system and ﬁnd common genotype or phenotype
backgrounds concerning drug metabolism in RVS extract-
responders.
In conclusion,drug developmentsfrom natural products
should be diﬀerently approached from the conventional
pharmaceutical paradigm, and we hope that these prelim-
inary results would stimulate further investigation into the
eﬀectivenessandtolerabilityofothernaturalproductsforthe
treatment of advanced cancers in clinical practice.
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